BioVie Inc. (BIVI) News
Track canonical SquawkNews coverage tagged to BIVI, BioVie Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BIVI: Bezisterim demonstrated significant symptom improvement and strong safety in Long COVID phase II
Bezisterim showed statistically significant improvements in fatigue, malaise, and cognitive symptoms among Long COVID patients with high baseline symptom burden, with a safety profile similar to placebo. Experts and pati
NEWS | Sep 15, 2026, 01:49 PM UTC
L
BIVI: Bezisterim showed significant benefit in symptomatic Long COVID patients and is advancing to Phase 3
Bezisterim demonstrated statistically significant improvements in fatigue, post-exertional malaise, and cognitive impairment among Long COVID patients with high baseline symptom burden, with a safety profile similar to p
NEWS | Sep 15, 2026, 11:49 AM UTC
L
BIVI: Bezisterim showed significant symptom improvement in Long COVID patients with high baseline burden
Topline results from a Phase 2 trial show bezisterim improved neurological symptoms in Long COVID patients with high baseline fatigue, cognitive impairment, or post-exertional malaise, with a safety profile similar to pl
NEWS | Sep 15, 2026, 11:33 AM UTC
L
BioVie Inc. (NASDAQ:BIVI) Reports Phase 2 ADDRESS—LC Topline Results
BioVie reported Phase 2 ADDRESS—LC topline data: no endpoints hit significance in the full ITT population, while pre—specified high—symptom subgroups showed statistically significant improvements on multiple measures. Sa
NEWS | Sep 15, 2026, 11:32 AM UTC
L
BioVie Announces Topline Results from Phase 2 ADDRESS—LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patientsin pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post—exertional malaiseBezisterim showed a consiste
NEWS | Sep 15, 2026, 11:31 AM UTC
L
BIVI - BioVie Announces Topline Results from Phase 2 ADDRESS—LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BIVI - BioVie Announces Topline Results from Phase 2 ADDRESS—LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
NEWS | Sep 15, 2026, 11:30 AM UTC
L
BIVI: Bezisterim showed no overall statistical benefit in Long COVID, but subgroup signals warrant further study
The Phase 2 ADDRESS-LC trial of bezisterim in Long COVID did not achieve statistical significance in the overall population, though some pre-specified subgroups showed promising signals. Further studies are planned to cl
NEWS | Sep 15, 2026, 10:39 AM UTC
L
BIVI - BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
BIVI - BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
NEWS | Sep 14, 2026, 08:01 PM UTC
M
Biovie updates Parkinson’s Phase 3 development program
BioVie Inc (BIVI) announced an update to its Parkinson’s Phase 3 development program.
EQUITY | Sep 08, 2026, 11:42 AM UTC
L
BioVie updates Parkinson’s Phase 3 program
BioVie (BIVI) announces an update to its Parkinson’s Phase 3 development program.
EQUITY | Sep 08, 2026, 11:30 AM UTC
L
Premarket gainers list led by GXAI, CURI and IVDA
A premarket movers list shows GXAI, CURI, IVDA, HLIT, OMER, FGI, BIVI, FRGT, ONDG and HHS among the top percentage gainers, with no catalyst supplied.
EQUITY | Aug 13, 2026, 09:43 AM UTC
L
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 54,373.37 while the NASDAQ fell 0.24% to 26,299.39. T
EARNINGS | Aug 06, 2026, 01:43 PM UTC
L
BIVI - BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
BIVI - BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
EQUITY | Aug 06, 2026, 11:31 AM UTC
M
BIVI Files $300M Mixed Shelf
BIVI and other companies file mixed shelf offerings with the SEC
EQUITY | Jun 22, 2026, 09:29 AM UTC